Shares of the company are trading at $10.17 which is just a bit below the 50 day moving average of $11.03 and impressively lower than the 200 day moving average of $11.37. The 50 day moving average went down by -7.77% and the 200 day average went down $-1.20 or -10.58%. 4,728 shares changed hands on Tuesday. Overall, volume was down 98.88% under the stocks normal daily volume.
Investors are more bullish on the company recently if you put credence in the decrease in short interest. The firm realized a fall in short interest of -1.80% as of September 29, 2017 from the last reporting period. Short interest decreased from 5,240,407 to 5,145,936 over that timeframe. With short interest at 5,145,936 and short average daily volume at 846,949, the short-interest ratio is 6.0 and the short interest percentage is 0.16% as of September 29.
The following firms have recently changed their position in BLCM. As of quarter end Cutler Group LP had bought a total of 6,133 shares growing its holdings by 413.8%. The value of the investment in BLCM went from $17,000 to $87,000 increasing 411.8% quarter to quarter. As of the end of the quarter Creative Planning had acquired 38,755 shares growing its stake by 33.2%. The value in dollars increased from $1,365,000 to $1,798,000 a change of 31.7% for the reporting period.
As of the end of the quarter Winslow, Evans & Crocker, Inc. had disposed of a total of 695 shares trimming its position 84.2%. The value of the investment in Bellicum Pharmaceuticals, Inc. decreased from $9,636,000 to $1,502,000 a change of $8,134,000 quarter over quarter. Meeder Asset Management Inc trimmed its ownership by shedding 16 shares a decrease of 15.0% from 06/30/2017 to 09/30/2017. Meeder Asset Management Inc owns 91 shares with a value of $1,000. The value of the position overall is down by 0.0%.
August 9 investment analysts at Raymond James left the stock rating at “Outperform” but moved down the price target to $18.00 from $29.00.
As of the last earnings report the EPS was $-2.94 and is estimated to be $-3.02 for the current year with 33,226,000 shares outstanding. Analysts expect next quarter’s EPS to be $-0.74 with next year’s EPS anticipated to be $-2.95.
Bellicum Pharmaceuticals, Inc., launched on July 14, 2004, is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Business’s product candidates include BPX-501, BPX-601 and BPX-701. The Business’s CID-based technologies include CaspaCIDe and GoCAR-T..